The startup develops a weight management technology that utilizes antibodies targeting gastrokine-one, a protein in the stomach linked to body fat accumulation in companion animals. This technology enables pet owners to effectively manage their pets' weight and prevent obesity-related health issues.
Funding
$38.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Obesity in companion animals is a growing concern, leading to various health issues and reduced quality of life. Current weight management methods can be difficult for both pets and their owners, often requiring strict diets and increased exercise.
Solution
Lumen Bio is developing a weight management technology based on antibodies that target gastrokine-1, a protein associated with body fat accumulation in companion animals. This approach aims to provide an easier and more effective way for pet owners to manage their pets' weight and prevent obesity-related health problems. The technology is currently in the research and development phase, with third-party labs ensuring product safety and efficacy. Lumen Bio envisions a future where pets can live longer and happier lives through proactive weight management.
Target Audience
The primary target audience includes pet owners looking for effective and easy-to-administer weight management solutions for their overweight companion animals.
Features
- Antibody-based technology targeting gastrokine-1
- Focus on weight management in overweight companion animals
- Aims to improve pet health and quality of life
- Currently undergoing third-party lab testing for safety and efficacy